Skip to main navigation
Skip to search
Skip to main content
Scholars @ UT Health San Antonio Home
Help & FAQ
English
Español
Home
Profiles
Research Units
Research output
Search by expertise, name or affiliation
Novel treatments for myelofibrosis: beyond JAK inhibitors
Douglas Tremblay,
Ruben Mesa
Research output
:
Contribution to journal
›
Review article
›
peer-review
2
Scopus citations
Overview
Fingerprint
Fingerprint
Dive into the research topics of 'Novel treatments for myelofibrosis: beyond JAK inhibitors'. Together they form a unique fingerprint.
Sort by
Weight
Alphabetically
Medicine and Dentistry
Combination Therapy
57%
Constitutional Symptoms
14%
Cytopenia
14%
Development
28%
Disease Exacerbation
14%
Diseases
14%
Epigenetic Modification
57%
Exercise
14%
Extramedullary Hematopoiesis
14%
Hematologic Malignancy
14%
Imetelstat
14%
Janus Kinase Inhibitor
71%
Maturation
14%
Myelofibrosis
100%
Nucleocytoplasmic Transport
14%
Patient
14%
Programmed Cell Death
14%
Selinexor
14%
Signal Transduction
14%
Splenomegaly
28%
Therapeutic Procedure
14%
Immunology and Microbiology
Apoptosis
14%
Bone Marrow
28%
Development
28%
Exercise
14%
Extramedullary Hematopoiesis
14%
Maturation
14%
Nucleocytoplasmic Transport
14%
Signal Transduction
14%
Biochemistry, Genetics and Molecular Biology
Apoptosis
14%
Development
28%
Exercise
14%
Extramedullary Hematopoiesis
14%
Maturation
14%
Nuclear Transport
14%
Signal Transduction
14%
Pharmacology, Toxicology and Pharmaceutical Science
Luspatercept
14%
Parsaclisib
14%
Tagraxofusp
14%
Neuroscience
Luspatercept
14%
Tagraxofusp
14%